

## **PUBLICATIONS**

### **ARTICLES IN REFEREED JOURNALS:**

1. **Moss SF**, Currie DC, Sheffield EA, Baxter M, Corrin B, Evans TW. Abnormal lung lymphatics and respiratory failure. *Thorax* 1989; 44: 432-3
2. **Moss SF**, Ind PW. Time course of recovery of lung function in sulfasalazine induced alveolitis. *Resp Med* 1991; 85: 73-75.
3. Beardshall K, **Moss S**, Gill J, Levi S, Ghosh P, Playford RJ, Calam J. Suppression of *Helicobacter pylori* reduces gastrin releasing peptide-stimulated gastrin release in duodenal ulcer patients. *Gut* 1992; 33: 601-3.
4. **Moss SF**, Thomas M, Mulnier C, McGill IG, Hodgson HJF. Intestinal lymphangiectasia associated with angiofollicular lymph node hyperplasia (Castleman's disease). *Gut* 1992; 33: 135-7.
5. **Moss SF**, Ghosh P, Thomas DM, Jackson JE, Calam J. Gastric antral vascular ectasia (watermelon stomach): Maintenance treatment with oestrogen-progesterone. *Gut* 1992; 33: 715-7.
6. **Moss SF**, Thomas DM, Ayesu K, Levi S, Calam J. Sucralfate diminishes basal acid output without affecting gastrin, *H pylori* or gastritis in duodenal ulcer patients. *Aliment Pharmacol Ther* 1992; 6: 251-8.
7. Butcher GP, Zambon M, **Moss SF**, Walters JRF. Addisonian crisis presenting with a normal short tetracosactrin test. *Postgrad Med J* 1992; 68: 465-6.
8. **Moss SF**, Legon S, Bishop AE, Polak JM, Calam J. Effect of *Helicobacter pylori* on gastric somatostatin in duodenal ulcer disease. *Lancet* 1992; 340: 930-2.
9. **Moss S**, Playford RJ, Ayesu K, Li SK, Calam J. pH dependent secretion of gastrin in duodenal ulcer disease: effect of suppressing *Helicobacter pylori*. *Digestion* 1992; 52: 173-8.
10. **Moss SF**, Lehner PJ, Gilbey SG, Kennedy A, Hughes JMB, Bloom SR, Hodgson HJF. Pleural involvement in the carcinoid syndrome. *Quart J Med* 1993; 86: 49-53.
11. **Moss SF**, Calam J. Acid secretion and sensitivity to gastrin in duodenal ulcer patients: effect of eradication of *H pylori*. *Gut* 1993; 34: 888-92.
12. Lacey SL, **Moss SF**, Taylor GW. Metronidazole uptake by sensitive and resistant isolates of *Helicobacter pylori*. *J Antimicrobial Chemotherapy* 1993; 32: 393-400.
13. **Moss SF**, Waheed A, Beardshall K, Gill J, Adamson D, Unwin R, Calam J. Use of endoscopic biopsies and microelectrodes to study human gastric acid secretion *in vitro*. *Neuropeptides* 1993; 25: 265-269.
14. **Moss SF**, Legon S, Calam J. Reciprocal changes in antral gastrin and somatostatin mRNA in pernicious anaemia. *Dig Dis Sci* 1994; 39: 321-6.
15. **Moss SF**, Legon S, Davies J, Calam J. Cytokine gene expression in *Helicobacter pylori*-associated antral gastritis. *Gut* 1994; 35: 1567-70.
16. Playford RJ, Mehta S, Upton P, Rentch R, **Moss S**, Calam J, Bloom S, Payne N, Ghatei M, Edwards R, Unwin R. Effect of peptide YY on human renal function. *Am J Physiol (Renal Fluid Electrolyte Physiol)* 1995; 268: F754-9.
17. **Moss SF**, Neugut AI, Garbowski GC, Wang S, Treat MR, Forde KA. *Helicobacter pylori* seroprevalence and colorectal neoplasia: evidence against an association. *J Natl Cancer Inst* 1995; 87: 762-3.
18. Sutter T, Arber N, **Moss SF**, Findling RI, Neugut AI, Weinstein IB, Holt PR. Frequent K-ras mutations in small bowel adenocarcinomas. *Dig Dis Sci* 1996; 41: 115-118.
19. **Moss SF**, Calam J, Agarwal B, Wang S, Holt PR. Induction of gastric epithelial apoptosis by *Helicobacter pylori*. *Gut* 1996; 38: 498-501.

20. Arber N, Hibshoosh H, **Moss SF**, Sutter T, Zhang Y, Begg M, Wang S, Weinstein IB, Holt PR. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. *Gastroenterology* 1996; 110: 669-674.
21. Guan RJ, **Moss SF**, Arber N, Krajewski S, Reed JC, Holt PR. 30kda Phosphorylated form of Bcl-2 protein in human colon. *Oncogene* 1996; 12: 2605-9.
22. Krajewska M, **Moss SF**, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. *Cancer Res* 1996; 56: 2422-7.
23. **Moss SF**, Agarwal B, Arber N, Guan RJ, Krajewska M, Krajewski S, Reed JC, Holt PR. Increased intestinal Bak expression results in apoptosis. *Biochem Biophys Res Comm* 1996; 223: 199-203.
24. Holt PR, Attilasoy E, Lindenbaum J, Ho SB, Lupton JR, McMahon D, **Moss SF**. Effect of acarbose on fecal nutrients, colonic pH and short chain fatty acids and rectal proliferative indices. *Metabolism* 1996; 45: 1179-1187
25. **Moss SF**, Attia L, Scholes JV, Walters JRF, Holt PR. Increased small intestinal apoptosis in coeliac disease. *Gut* 1996; 39: 811-817.
26. **Moss SF**, Scholes JV, Holt PR. Abnormalities of epithelial apoptosis in multistep colorectal neoplasia demonstrated by terminal deoxyuridine nick end labeling. *Dig Dis Sci* 1996; 41: 2238-2247.
27. **Moss SF**, Liu T, Petrotos A, Hsu TM, Gold LI, Holt PR. Inward growth of colonic adenomatous Polyps. *Gastroenterology* 1996; 111: 1425-32.
28. Holt PR, **Moss SF**, Kapetanakis AM, Petrotos A, Wang S. Is Ki-67 a better proliferative marker in the colon than PCNA? *Cancer Epidem Biomarkers Prev* 1997; 6: 131-5
29. Peek RM, **Moss SF**, Tham KT, Perez-Perez GI, Miller GG, Atherton JC, Holt PR, Blaser MJ. *Helicobacter pylori* cagA+ strains and dissociation of gastric epithelial proliferation from apoptosis *J Natl Cancer Inst* 1997; 89: 863-8.
30. Chen G, Sordillo EM, Ramey WG, Reidy J, Holt PR, Krajewski S, Reed JC, Blaser MJ, **Moss SF**. Apoptosis in gastric epithelial cells is induced by *Helicobacter pylori* and accompanied by increased expression of Bak. *Biochem Biophys Res Comm* 1997; 39: 626-632.
31. Holt PR, **Moss SF**, Heydari AR, Richardson A. Diet restriction increases apoptosis in the gut of aging rats. *J Gerontology: Biological Sciences*. 1998; 53A: B168-172.
32. Holt PR, Attilasoy EO, Gilman J, Guss J, **Moss SF**, Newmark H, Fan K, Yang K, Lipkin M. Modulation of abnormal colonic epithelial cell proliferation and differentiation by low fat dairy foods. *JAMA* 1998; 280: 1074-9.
33. Shirin H, Sordillo EM, Oh SH, Yamamoto H, Delohery T, Weinstein IB, **Moss SF**. *Helicobacter pylori* inhibits the G1 to S transition in AGS gastric epithelial cells. *Cancer Res* 1999; 59: 2277-81.
34. Shirin H, Dotan I, Papa M, Maaravi, Aeed H, Zaidel L, Matas Z, Bruck, S, **Moss SF**, Halpern Z, Oren R. Inhibition of concanavalin A-induced acute T cell dependent hepatic damage in mice by hypothyroidism. *Liver* 1999; 19: 206-211.
35. Liu LU, Holt PR, Krivosheyev V, **Moss SF**. Human right and left colon differ in epithelial cell apoptosis and in expression of Bak, a pro-apoptotic Bcl-2 homolog. *Gut* 1999;45: 45-50.
36. Agarwal B, Bhendwal S, Halmos B, **Moss SF**, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. *Clin Cancer Res* 1999; 5: 2223-9.
37. **Moss SF**, Valle J, Abdalla AM, Wang S, Siurala M, Sipponen P. Gastric cellular turnover and the development of atrophy after 31 years of follow up: a case-control study. *Am J Gastroenterology* 1999; 94: 2109-14.
38. **Moss SF**, Krivosheyev V, De Souza A, Chin K, Gaetz HP, Chaudhary N, Worman HJ, Holt PR. Nuclear lamin expression in gastrointestinal tract neoplasms. *Gut* 1999; 45: 723-729.
39. Oren R, Dabeva MD, Karnezis AN, Petkov PM, Rosencrantz R, Sandhu JP, **Moss SF**, Wang S, Hurston E, Laconi E, Holt PR, Thung SN, Zhu L, Shafritz DA. Role of thyroid hormone in stimulating liver repopulation by transplanted hepatocytes. *Hepatology* 1999; 30: 903-913.

40. Peek RM, Wirth HP, **Moss SF**, Yang M, Abdalla AM, Tham KT, Zhang T, Tang LH, Modlin IM, Blaser MJ. *Helicobacter pylori* alters gastric epithelial cell cycle events and gastrin secretion in Mongolian gerbils. *Gastroenterology* 2000; 118:48-59.
41. Shirin H, Sordillo EM, Kolevska T, Hibshoosh H, Kawabata Y, Oh S, Kuebler JF, Delohery T, Weghorst CM, Weinstein IB, **Moss SF**. Chronic *Helicobacter pylori* infection induces an apoptosis-resistant phenotype associated with decreased p27<sup>kip1</sup>. *Infection & Immunity* 2000; 68: 5321-8.
42. Kidd M, Tang LH, Modlin IM, Zhang T, Chin K, Holt PR, **Moss SF**. Gastrin-mediated alterations in gastric epithelial apoptosis and proliferation in a *Mastomys* rodent model of gastric neoplasia. *Digestion* 2000; 62: 143-151.
43. Shirin H, Pinto JT, Kawabata Y, Soh J-W, Delohery T, **Moss SF**, Murty V, Rivlin RS, Holt PR, Weinstein IB. Antiproliferative effects of S-allylmercaptocysteine on colon cancer cells, when tested alone or in combination with sulindac. *Cancer Res* 2001; 61: 725-731.
44. Shirin H, Kenet G, Shevah O, Wardi Y, Birkenfeld S, Shahmurov M, Bruck R, Niv Y, **Moss SF**, Avni Y. Evaluation of a novel continuous real time <sup>13</sup>C urea breath analyser for *Helicobacter pylori*. *Aliment Pharmacol Ther* 2001; 15: 389-394.
45. **Moss SF**, Sordillo EM, Abdalla AM, Makarov V, Hanzely Z, Perez-Perez GI, Blaser JM, Holt PR. Increased gastric epithelial cell apoptosis associated with colonization with cagA<sup>+</sup> *Helicobacter pylori* strains. *Cancer Res* 2001; 61: 1406-11.
46. Shirin H, Pinto JT, Liu L, Merzianu M, Sordillo EM, **Moss SF**. *Helicobacter pylori* decreases gastric mucosal glutathione *Cancer Letts* 2001;164:127-133.
47. Israel DA, Salama N, Arnold CN, **Moss SF**, Ando T, Wirth H-P, Tham KT, Camorlinga M, Blaser MJ, Falkow S, Peek RM. *Helicobacter pylori* strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses. *J Clin Invest* 2001; 107: 611-620.
48. Morgenstern S, Koren R, **Moss SF**, Fraser G, Okon E, Niv Y. Does *Helicobacter pylori* affect gastric mucin expression? Relationship between gastric antral mucin expression and *H. pylori* colonization. *Eur J Gastroenterol Hepatol* 2001;13:19-23.
49. Marchbank T, Cox HM, Goodlad RA, Giraud AS, **Moss SF**, Wright NA, Jankowski J, Playford.RJ. Effect of ectopic expression of rat trefoil factor family 3 (TFF3, intestinal trefoil factor) in the jejunum of transgenic mice. *J Biol Chem* 2001;276:24088-96.
50. Holt PR, Wolper C, **Moss SF**, Yang K, Lipkin M. Comparison of calcium supplementation or low fat dairy foods upon epithelial cell proliferation and differentiation. *Nutr Cancer* 2001;41:150-155.
51. Holt PR, Arber N, Halmos B, Forde K, Kissileff H, McGlynn KA, **Moss SF**, Yang K, Lipkin ML. Colonic epithelial cell proliferation decreases with increasing levels of serum 25 Hydroxy vitamin D. *Cancer Epidem Biomarkers Prev* 2002; 11: 113-9.
52. Shirin H, Frenkel D, Shevah O, Levine A, Bruck R, **Moss SF**, Niv Y, Avni Y. Effect of proton pump inhibitors on the continuous real time <sup>13</sup>C-urea breath test. *Am J Gastroenterol* 2003; 98: 46-50.
53. Shirin H, Hibshoosh H, Kawabata Y, Weinstein IB, **Moss SF**. p16<sup>Ink4a</sup> is overexpressed in *Helicobacter pylori*-associated chronic gastritis and is associated with increased epithelial apoptosis. *Helicobacter* 2003; 8: 66-71.
54. Eguchi H, Herschenhous N, Kuzushita N, **Moss SF**. *Helicobacter pylori* increases proteasome-mediated degradation of p27<sup>kip1</sup> in gastric epithelial cells. *Cancer Res* 2003; 63: 4739-4746.
55. Shirin H, Sadan O, Shevah O, Bruck R, Boaz M, **Moss SF**, Everon S, Glezerman M, Avni Y. Positive serology for *Helicobacter pylori* and vomiting in pregnancy. *Arch Gynecol Obstet* 2004;270:10-4.
56. Eguchi H, Carpentier S, Kim SS, **Moss SF**. p27<sup>kip1</sup> regulates the apoptotic response of gastric epithelial cells to *Helicobacter pylori*. *Gut* 2004; 53: 797-804.
57. Levine A, Shevah O, Shabat-Sehayek V, Aeed H., Boaz M. **Moss SF**, Niv Y, Avni Y, Shirin H. Masking of <sup>13</sup>C urea breath test by proton pump inhibitors is dependent on type of medication: Comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. *Aliment Pharmacol Ther* 2004;20:117-22.

58. Xu H, Chaturvedi R, Cheng Y, Bussiere FI, Asim M, Yao MD, Potosky D, Meltzer SJ, Rhee JG, Kim SS, **Moss SF**, Hacker A, Wang Y, Casero RA, Wilson KT. Spermine oxidation induced by *Helicobacter pylori* results in apoptosis and DNA damage: Implications for gastric carcinogenesis. *Cancer Res* 2004; 64: 8521-25.
59. Shirin H, Kravtsov V, Shahmurov M, Boaz M, Petchenko P, Bruck R, **Moss SF**, Avni Y, Avinoach I. p27<sup>kip1</sup> expression is inversely related to the grade of gastric MALT lymphoma. *Int J Gastrointest Cancer* 2005; 35: 25-32.
60. Kethu SR, Davis GC, Reinert SE, Ramzan UC, **Moss SF**. Low utility of endoscopy for suspected upper gastrointestinal bleeding occurring in hospitalized patients. *S. Med J* 2005; 98: 170-175.
61. Resnick MB, Gavilanez M, Newton E, Konkin T, Bhattacharya B, Britt DE, Sabo E, **Moss SF**. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation *Hum Pathol.* 2005;36:886-92.
62. Kuzushita N, Rogers AB, Monti NA, Whary MT, Park MJ, Aswad BI, Shirin H, Koff A, Eguchi E, **Moss SF**. p27kip1 Deficiency confers susceptibility to gastric carcinogenesis in *Helicobacter pylori* infected mice. *Gastroenterology* 2005; 129: 1544-1556.
63. Kim SS, Meitner P, Konkin TA, Cho YS, Resnick MB, **Moss SF**. Altered Expression of Skp2, c-Myc and p27 proteins but not mRNA after *H. pylori* eradication in chronic gastritis. *Mod Pathology* 2006;19:49-58.
64. Shirin H, **Moss SF**, Stark B, Holt PR, Weinstein IB, Sordillo EM. Inhibition of *H. pylori* by the nonsteroidal anti-inflammatory drug sulindac. *J Gastroenterol Hepatol* 2006 (in press).
65. Zhang Y, Cristofaro P, Silbermann R, Pusch O, Boden D, Konkin T, Hovanesian V, Monfils PR, Resnick M, **Moss SF**, Ramratnam B. Engineering mucosal RNA interference *in vivo*. *Mol Ther* 2006. (in press).
66. Resnick MB, Sabo E, Kim SS, Cho YS, Meitner P, Kim HK, Tavares R, **Moss SF**. Global analysis of the human gastric epithelial transcriptome altered by *H. pylori* eradication *in vivo*. *Gut* 2006 (in press).

## BOOK CHAPTERS, REVIEWS & EDITORIALS

1. **Moss SF**, Calam J. Pathophysiology of Gastrointestinal Hormones. *Current Opinion in Gastroenterology.* 1990; 6: 877-881.
2. **Moss S**, Calam J. *Helicobacter pylori* and peptic ulcer: The present position. *Gut* 1992; 33: 289-292.
3. Calam J, **Moss SF**. Chronic peptic ulcer: Aetiology and epidemiology; Chronic duodenal ulcer: clinical features, investigation and medical treatment in 'Gastroenterology; Clinical science and practice', Bouchier IAD, Hodgson HJF, Allen RN & Keighley MRB, Eds. 2nd edition. WB Saunders, London, 1993.
4. **Moss SF**, Calam J. Reply to reviewers comments in: Selected summaries: *Helicobacter pylori* and duodenal ulcer disease: the somatostatin link? McHenry L Jr, Vuyyuru L, Schubert ML. *Gastroenterology* 1993; 104: 1573-5.
5. **Moss SF**, Holt PR. Celiac disease; Malabsorption; Tropical sprue; Bacterial overgrowth syndromes; Whipple's disease; Lactase deficiency; Eosinophilic gastroenteritis (**7 chapters**) in 'Medicine for the Practising Physician', Hurst JW, Editor-in-chief. 4th ed. Appleton & Lange, Stamford, CT, 1996.
6. **Moss SF**. Treatment Of *H Pylori* Infection - Who, How And When. *Resident & Staff Physician* 1996; 42: 11-18.
7. **Moss SF**, Wright NA. Molecular Aspects Of Mucosal Repair: Summary. *Yale J Biol Med* 1997: 69: 155-158.
8. **Moss SF**. Cellular markers in the gastric precancerous process. *Aliment Pharmacol Ther* 1998; 12 (suppl 1): 250-36.

9. **Moss SF**, Fendrick AM, Cave DR, Modlin IM. *Helicobacter pylori* -- More Light, Less Heat. *Am J Gastroenterol* 1998; 93: 306-310.
10. **Moss SF**. Epithelial cell turnover and apoptosis. In: *Helicobacter pylori: Basic Mechanisms to Clinical Cure*, 1998. Hunt RH, Tytgat GN Eds. 2nd ed. Kluwer Academic Publishing, UK, 1998.
11. **Moss SF**. *H. pylori* and apoptosis - Is there consensus? Invited Commentary. *Italian J Gastro Hepatol* 1998; 30: 160-1.
12. Shirin H, **Moss SF**. Leading article: *Helicobacter pylori*-Induced Apoptosis. *Gut* 1998; 43: 592-4
13. **Moss SF**, Arnold R, Tytgat GNJ, Spechler SJ, Delle Fave G, Rosin D, Jensen RT, Modlin IM. Consensus statement for management of gastroesophageal reflux disease. Result of workshop meeting at Yale University School of Medicine, Department of Surgery. November 16 and 17, 1997. *J Clin Gastroenterol* 1998; 27: 6-12.
14. **Moss SF**. *H. pylori* and apoptosis. *Yale J Biol Med* 1998; 71: 53-61.
15. Shirin H, **Moss SF**. A key cytokine unlocks the door. *Gut* 1999; 45: 5-6.
16. **Moss SF**. The carcinogenic effect of *H. pylori* on the gastric epithelial cell. *J Physiol Pharmacol* 1999; 50: 847-56.
17. **Moss SF**, Bardhan KD, Quigley EMM, Rosin RD, Wright NA, Modlin IM. Barrett's oesophagus – current status, future challenges. <http://www.gastrohep.com/freespeech/freespeech.asp?id=39>. Posted 2001;17 April.
18. **Moss SF**. *H. pylori* – carcinogenic mechanisms. In: A. Moran, ed. *H. pylori* 2001. CD-ROM. Normedia, 2001.
19. Shirin H, Weinstein IB, **Moss SF**. Effects of *H. pylori* infection of gastric epithelial cells on cell cycle control. *Front Bioscience* 2001; 6: e104-118.
20. Sordillo EM, **Moss SF**. Apoptosis and the pathogenesis of *Helicobacter pylori* – related disease. In: *H. pylori* infection and immunity. Yamamoto Y, Friedman H, Hoffman P, eds. Kluwer Academic/Plenum Publishing, NY 2002.
21. **Moss SF**, Modlin IM. Irritable bowel and the irritable physician. *J Clin Gastro* 2002; 35 (Suppl.): S68-S70.
22. Eguchi H, **Moss SF**. *Helicobacter pylori*: for life or death? *Mol Pathol* 2002;55:284-285.
23. Sordillo EM, **Moss SF**. *Helicobacter pylori* and apoptosis. *Methods Enzymol* 2002;358:319-34.
24. **Moss SF**. Basic science @lert: Runx 3, apoptosis nil. A new gastric tumour suppresser. *Gut* 2003;52:12-13.
25. **Moss SF**, Eguchi H. Regulation of gastric apoptosis and proliferation. In: Falk symposium 132. Disease progression and carcinogenesis in the gastrointestinal tract. Galle PR, Gerken G, Schmidt WE, Wiedenmann B, eds. Kluwer Academic Publishers, Dordrecht, Germany.
26. **Moss SF**. Mechanisms of injury: the effects of *H. pylori* on cell cycle control. In: *Basic Mechanisms to Clinical Cure*, 2002. Hunt RH, Tytgat GN Eds. 2nd ed. Kluwer Academic Publishers, UK.
27. Moss SF, Sood S. *Helicobacter pylori*. *Current Opinion in Infectious Diseases* 2003; 16: 445-451.
28. **Moss SF**, Armstrong D, Arnold R, Ferenci P, Fock KM, Holtmann G, McCarthy DM, Moraes-Filho JP, Playford R, Spechler SJ, Stanghellini V, Modlin IM. GERD 2003 – A Consensus on the way ahead. *Digestion* 2003; 67:111-7.
29. **Moss SF**, Shirin H. Epidemiology and Molecular Epidemiology of Gastric Cancer. In: *Principles and Practice of Gastrointestinal Oncology*. Abbruzzese J, Evans DB, Willett C, Hamilton S, Eds. Oxford University Press, NY, 2004.
30. Kethu SR, **Moss SF**. Gastritis and peptic ulcer disease. In: *Conn's current therapy*. Rakel RE & Bope E, eds. 56<sup>th</sup> ed. WB Saunders, Philadelphia, PA, 2004.
31. Modlin IM, **Moss SF**, Kidd M, Lye KD. Gastroesophageal Reflux Disease - Then and Now. *J Clin Gastro* 2004; 38: 390-402.
32. **Moss SF**, Blaser MJ. Mechanisms of Disease: inflammation and the origins of cancer. *Nature Clinical Practice Oncology* 2005; 2: 90-97.

33. **Moss SF**, Reis T. Media Watch. Historical resources at Ivy League universities: Brown University. *Lancet Oncology* 2005; 6: 748.
34. Malfertheiner P, Fass R, Quigley EMM, Modlin IM, Malagelada JR, **Moss SF**, Holtmann G, Goh K-L, Katelaris P, Stanghellini V, Talley NJ, Tytgat GN, Wright NA. Review article: From gastrin to gastro-oesophageal reflux disease - a century of acid suppression. *Aliment Pharmacol Ther* 2006; 23: 683-690.

## LETTERS

1. **Moss SF**, Tonge K, Walters JRF. Cholestasis associated with cinnarazine. *BMJ* 1990; 301: 1282
2. **Moss SF**, Ind PW. Ethnic differences in consultation rates. *BMJ* 1990; 300: 47
3. **Moss SF**, Calam J. Acid hypersecretion in duodenal ulcer patients. *Am J Gastroenterology* 1994; 89: 1598-9.
4. Middleton SJ, Reynolds PD, Shorthouse M, Hunter JO, **Moss S**. Nitric oxide synthase in gastric mucosa. *Gut* 1995; 36: 942.
5. **Moss SF**. The US residency programme. *Postgrad Med J* 1995; 71: 639.
6. **Moss SF**, Holt PR. Apoptosis in the Intestine. *Gastroenterology* 1996; 111: 567-8.
7. Abdalla AM, Sordillo EM, Hanzely Z, Perez-Perez GI, Blaser MJ, Holt PR, **Moss SF**. Insensitivity of the CLO test for *H pylori*, especially in the elderly. *Gastroenterology* 1998; 115: 243-4.
8. Eid R, **Moss SF**. *Helicobacter pylori* infection and the development of gastric cancer. *N Engl J Med* 2002; 346: 66.
9. Shirin H, Pinto JT, **Moss SF**. Influence of clinical factors, drug use, and food intake on the glutathione system. *Gut* 2003; 52: 154

## ABSTRACTS

1. **Moss SF**, Rudolf M, Owen R, Ind PW. Mechanical ventilation for severe acute asthma in a district general hospital in the 1980s. *Am Rev Respir Dis* 1990; 141: A398
2. Davies S, **Moss SF**, Longstaff P, Ind PW. Casualty assessment of asthma at a district general hospital. *Thorax* 1990; 45: 818
3. Lane RJM, de Belleruche J, **Moss SF**, Horne G, Bandopadhyay R, Clifford Rose F. An abnormality of glycine metabolism in motor neuron disease patients. *J Neurol Neurosurg Psychiatry* 1990; 53: 180
4. **Moss S**, Ayesu K, Calam J. Gastrin and gastric acid output 1 year after eradication of *Helicobacter pylori* in duodenal ulcer patients. *Regul Peptides* 1991; 35: 251
5. **Moss S**, Ayesu K, Li SK, Calam J. Gastrin, gastric acid and pepsin responses during intragastric titration in duodenal ulcer patients : effect of suppressing *Helicobacter pylori*. *Gut* 1991; 32: A1206-7.
6. Gupta R, **Moss S**, Thomas DM, Abbott F, Rees A, Calam J. *Helicobacter pylori* increases release of interleukin-8 : a potent attractant of neutrophils (abstract). *Gut* 1991; 32: A1206.
7. **Moss SF**, Bishop AE, Polak JM, Calam J. Increased antral somatostatin-immunoreactive cell density after eradication of *Helicobacter pylori*. *Irish J Med Sci* 1992; 161 (suppl 10): 30-31.
8. **Moss SF**, Legon S, Calam J. Gastrin and somatostatin mRNA in human endoscopic gastric biopsies. *Gut* 1992; 33 (suppl 1): S74.
9. **Moss SF**, Legon S, Calam J. *Helicobacter pylori* infection decreases gastric somatostatin mRNA in duodenal ulcer patients. *Gut* 1992; 33 (suppl 2): S27.
10. **Moss SF**, Legon S, Calam J. Somatostatin regulates antral gastrin synthesis in pernicious anaemia. *Gut* 1992; 33 (suppl 2) : S61.

11. **Moss SF**, Calam J. Changes in acid secretion and parietal cell sensitivity to gastrin in duodenal ulcer patients after eradication of *H pylori*. *Gut* 1992; 33 (suppl 2): S 28.
12. **Moss SF**, Unwin R, Waheed A, Calam J. Inhibition of acid secretion from human endoscopic biopsies by the gastrin receptor antagonist Cam-1028 *Gut* 1992; 33 (suppl 2): S32.
13. **Moss SF**, Waheed A, Unwin R, Thomas DM, Calam J. Secretion of acid by human gastric antrum biopsies. *Gastroenterology* 1992; 102: A128.
14. Calam J, **Moss SF**. Pathophysiology of gastrin release: reciprocal changes in gastrin and somatostatin mRNAs in achlorhydria. *Quart J Med* 1993; 86: 547.
15. Toker N, **Moss SF**, Legon S, Calam J. *H pylori* lowers duodenal but not corpus somatostatin RNA, in DU patients. *Gut* 1994; 35: (suppl 2), S18.
16. **Moss SF**, Davies J, Legon S, Calam J. Interleukin-8 and tumour necrosis factor- $\alpha$  RNA in antral mucosa of duodenal ulcer patients: effect of eradicating *H pylori*. *Gut* 1994; 35 (suppl 2): S4.
17. **Moss SF**, Legon S, Davies J, Calam J. *Helicobacter pylori* increases gastric mucosal interleukin-8 and tumour necrosis factor  $\alpha$  mRNA. *Gastroenterology* 1994; 106: A143.
18. Guan R, **Moss SF**, Arber N, Krajewski S, Reed JC, Holt PR. Bcl-2 and Bax expression in human colonocytes. *Proc Am Assoc Cancer Res* 1995; 36: 11.
19. Arber N, Miyake M, Sutter T, **Moss S**, Holt PR, Weinstein IB. K-ras transformed rat enterocytes overexpress Rb and cyclin D1. *Proc Am Assoc Cancer Res* 1995; 36: 34.
20. Middleton SJ, Calam J, **Moss SF**, Shorthouse M, Hunter JO. Effect of *Helicobacter pylori* on gastric mucosal ammonium concentrations. *Gut* 1995; 36 (suppl 1): A9.
21. Middleton SJ, **Moss SF**, Shorthouse M, Calam J, Hunter JO. Is gastric mucosal nitric oxide synthase activity increased in patients with *H pylori* associated duodenal ulceration? *Gut* 1995; 36 (suppl 1): A10.
22. **Moss SF**, Scholes J, Wang S, Holt PR. Progressively disordered apoptosis during the multistep process of colorectal carcinogenesis. *Gastroenterology* 1995; 108: A511.
23. **Moss SF**, Arber N, Guan R, Heydari AR, Krajewski S, Reed JC, Holt PR. Differences in epithelial apoptosis and apoptosis-related gene expression between the rat small and large intestine. *Gastroenterology* 1995; 108: A741.
24. **Moss SF**, Calam J, Agarwal B, Wang S, Holt PR. *Helicobacter pylori* infection induces gastric epithelial apoptosis *in vivo*. *Gastroenterology* 1995; 108: A171.
25. Attia AL, **Moss SF**, Walters JRF, Wang S, Holt PR. Increased small bowel epithelial apoptosis reflects celiac sprue activity. *Gastroenterology* 1995; 108: A271.
26. **Moss SF**, Neugut AI, Garbowski GC, Wang S, Treat MR, Forde KA. *Helicobacter pylori* and colorectal neoplasia: evidence against an association. *Gastroenterology* 1995; 108: A511.
27. Arber N, Sutter T, **Moss SF**, Hibshoosh H, Zhang Y, Begg M, Wang S, Weinstein IB, Holt PR. Cyclin D1 overexpression is an early event in multistep colon carcinogenesis. *Gastroenterology* 1995 108: A445.
28. Arber N, Sutter T, **Moss SF**, Miyake M, Holt PR, Weinstein IB. Overexpression of the retinoblastoma (Rb) and cyclin D1 genes in K-ras transformed rat enterocytes. *Gastroenterology* 1995; 108: A445.
29. Sutter T, Arber N, **Moss SF**, Findling R, Weinstein IB, Holt P. Frequent K-ras mutations in small bowel adenocarcinomas. *Gastroenterology* 1995; 108: A542.
30. Krajewska M, **Moss SF**, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of Bcl-X in primary colorectal adenocarcinomas. *Proc Am Assoc Cancer Res* 1996; 37: 572.
31. Liu T, **Moss SF**, Gold L, Petrotos A, Holt PR. Inward Growth of colonic Adenomatous Polyps. *Gastroenterology* 1996; 110: A551
32. Peek RM, **Moss SF**, Tham KT, Perez-Perez GI, Miller GG, Holt PR, Blaser MJ. Infection with *H. pylori* CagA+ strains dissociates gastric epithelial proliferation from apoptosis. *Gastroenterology* 1996; 110: A575

33. **Moss SF**, Krajewska M, Krajewski S, Guan RJ, Reed JC, Holt PR. Reciprocal expression of Bcl-X<sub>L</sub> and Bak in multistep colorectal neoplasia. *Gastroenterology* 1996; 110:A562
34. N Arber, H Hibshoosh, **Moss SF**, Lightdale C, Zhang Y, Heitjan D, Yap E, Gammon M, Neugut AI, Weinstein IB, Holt PR. Increased expression of cyclin D1 is a common and early event in gastrointestinal cancers. *Gastroenterology* 1996; 110:A485
35. Guan RJ, **Moss SF**, Arber N, Krajewski S, Reed JC, Holt PR. Bcl-2 phosphorylation occurs in the human colon. *Gastroenterology* 1996; 110:A524
36. **SF Moss**, N Arber, H Hibshoosh, S Wang, MD Gammon, IB Weinstein, PR Holt. Cyclin D1 expression in gastric carcinogenesis. *Gut* 1996; 39 (suppl 2): A18-19.
37. **Moss SF**, Alam S, Pou R, Wang S, Krajewski S, Reed JC. Holt PR. Increased expression of the pro-apoptotic Bcl-2 homologue, Bak, in *H. pylori* infected gastric mucosa. *Gastroenterology* 1997; 112: A225.
38. B Agarwal, **SF Moss**, B Halmos, G Chen, S Krajewski, JC Reed, PR Holt. Lovastatin causes apoptosis in intestinal cell lines. *Gastroenterology* 1997;112: A531.
39. L Liu, **SF Moss**, S Wang, S Krajewski, JC Reed, PR Holt. Right & left colon differ in epithelial cell apoptosis and in expression of the pro-apoptotic Bcl-2 homologue, Bak. *Gastroenterology* 1997; 112: A 225.
40. G Chen, Z Hanzely, W Ramey, PR Holt, **SF Moss**. Apoptosis in gastric epithelial cells induced by *H.pylori* is accompanied by altered expression of the Bcl-2 protein family. *Gut* 1997: 41 (suppl 1): A16.
41. AM Abdalla, Z Hanzely, GI Perez-Perez, MJ Blaser, PR Holt, **SF Moss**, EM Sordillo. The biopsy urease (CLOtest™) is inadequate for diagnosis of *Helicobacter pylori* infection in the elderly. *Clin Infect Dis* 1997; 25: 368.
42. B Halmos, B Agarwal, **SF Moss**, WG Ramey, PR Holt. Lovastatin causes p53 dependent apoptosis in intestinal IEC-18 cells. *Proc Am Assoc Cancer Res* 1998; 39:68.
43. B Agarwal, B Halmos, **SF Moss**, WG Ramey, PR Holt. Lovastatin sensitizes colon cancer HT-29 cells to apoptosis induced by chemotherapeutic agents. *Proc Am Assoc Cancer Res* 1998;39:574.
44. B Halmos, B Agarwal, WG Ramey, **SF Moss**, PR Holt. Apoptosis and morphological changes in IEC-18 cells are inhibited by cycloheximide. *Gastroenterology* 1998;114:A604.
45. B Agarwal, B Halmos, S Bhendwal, WG Ramey, **SF Moss**, PR Holt. Lovastatin-induced sensitization of colon cancer cells to apoptosis is independent of ras and is reversed by geranylgeraniol but not by farnesol. *Gastroenterology* 1998;114:A554
46. H Shirin, S Oh, H Yamamoto, EM Sordillo, T Delohery, PR Holt, IB Weinstein, **SF Moss**. *H pylori* induces p21<sup>cip1</sup> & inhibits G1/S progression while inducing apoptosis in synchronized gastric epithelial cells. *Gastroenterology* 1998; 114: A287.
47. **SF Moss**, J Valle, AM Abdalla, M Siurala, P Sipponen. Gastric cellular turnover and the development of atrophy after 31 years of follow up: a case-control study. *Gastroenterology* 1998; 114:A648.
48. AM Abdalla, V Krivosheyev, Z Hanzely, PR Holt, GI Perez-Perez, MJ Blaser, **SF Moss**. Increased epithelial cell turnover in antrum and corpus of *H. pylori*- infected stomach, irrespective of *cagA* status. *Gastroenterology* 1998; 114: A50.
49. Peek RM, **Moss SF**, Cover TL, Wirth HP, Tham KT, Atherton JC, Holt PR, Blaser MJ. *Helicobacter pylori* VacA S1a strains attenuate apoptosis in vitro and in vivo through a toxin-independent mechanism. *Gastroenterology* 1998; 114: A256.
50. M. Kidd, **SF Moss**, LH Tang, T Zhang, K Chin, P Holt, IM Modlin. Gastrin-mediated alterations in gastric epithelial apoptosis and proliferation in a rodent model of gastric neoplasia. *Gastroenterology* 1998; 114: A622.
51. Shirin H, Oh SH, Sordillo EM, Delohery T, Weinstein IB, Holt PR, **Moss SF**. Apoptosis associated with *H pylori* differs between exponentially growing and starved-refed AGS gastric epithelial cells. *Gut* 1998; 43 (suppl 2): A17.

52. Oren R, Dabeva M, Petkov PM, **Moss S**, Wang S, Hurston E, Laconi E, Holt PR, Thung SN, Shafritz DA. Role of thyroid hormone in stimulating liver repopulation by transplanted hepatocytes *Hepatology* 1998; 28: 503A.
53. Kolevska TK, Shirin H, Delohery T, **Moss SF**. Chronic infection of gastric epithelial cells by *Helicobacter pylori* induces cross- resistance to apoptosis caused by radiation, hypoxemia, VP16, 5FU and lovastatin. *Proc Am Assoc Cancer Res* 1999; 40: 322
54. Shirin H, Sordillo EM, Delohery T, Holt PR, Weinstein IB, **Moss SF**. Effects of *H. pylori* on cell cycle progression, apoptosis and signal transduction in the AGS human gastric carcinoma cell line. *Proc Am Assoc Cancer Res* 1999; 40: 28
55. Shirin H, Sordillo EM, Delohery T, Weinstein IB, **Moss SF**. Reduced expression of the cyclin-dependent kinase inhibitor, p27<sup>kip1</sup> in subclones of AGS gastric epithelial cells resistant to *H. pylori*-induced apoptosis. *Gastroenterology* 1999; 116: A503.
56. Shirin H, Oh SH, Sordillo EM, Kolevska TK, Delohery T, Weinstein IB, **Moss SF**. Chronic exposure of gastric epithelial cells to *H. pylori* leads to generalized resistance to apoptosis. *Gastroenterology* 1999; 116: A312
57. Peek RM, Wirth HP, **Moss SF**, Abdalla AM, Voodarla A, Yang M, Zhang T, Tang LH, Modlin IM, Tham KT, Blaser MJ. Experimental infection with *Helicobacter pylori* alters gastric epithelial cell cycle events and gastrin secretion in Mongolian gerbils, independent of *cagA* or *VacA*. *Gastroenterology* 1999;116: A484.
58. Wilson KT, Ramanujam KS, Shirin H, Delohery T, **Moss SF**. Prostaglandin E2 inhibits *Helicobacter pylori*-induced apoptosis. *Gastroenterology* 1999;116: A530.
59. Luo X-L, Ramanujam KS, Zhao H-M, **Moss SF**, Russell RG, Drachenberg CB, Wilson KT Protective role of COX- 2 in *H. pylori* gastritis: exacerbation of inflammation in COX-2 knockout mice. *Gastroenterology* 1999; 116: A767
60. Marchbank T, Cox H, Goodlad R, Giraud AS, **Moss S**, Wright NA, Playford RJ. Transgenic mice overexpressing TFF (rat intestinal trefoil factor) within the jejunum have an increased regional resistance to intestinal damage but no difference in cell migration or apoptosis. *Gastroenterology* 1999;116: A920.
61. Shirin H, Sordillo EM, Kawabata Y, Hibshoosh H, Kuebler JF, Kolevska T, Delohery T, Weinstein IB, **Moss SF**. The cyclin dependent kinase inhibitor p27<sup>kip1</sup>, a putative tumor suppressor gene, is reduced by *Helicobacter pylori*: an early event in gastric carcinogenesis? *Gut* 1999; 45 (suppl 3): A2.
62. **Moss SF**. The carcinogenic effect of *H. pylori* on the gastric epithelial cell. *J Physiol Pharmacol* 1999; 50 (suppl 2): 34.
63. Shirin H, **Moss SF**, Harte B, Weinstein IB, Holt PR, Sordillo EM. Inhibition of *Helicobacter pylori* growth by sulindac. *Gastroenterology* 2000; 118: A880.
64. Shirin H, Kawabata Y, Hibshoosh H, Andrescu D, Weinstein IB, **Moss SF**. Expression of the cyclin-dependent kinase inhibitor p27<sup>kip1</sup> is reduced in gastric epithelial cells of patients with *Helicobacter pylori*-induced gastritis. *Gastroenterology* 2000; 118: A763.
65. Shirin H, Shevah O, Kenet G, Wardi Y, Shahmurov M, Bruck R, **Moss SF**, Avni Y. Evaluation of a novel continuous real-time <sup>13</sup>C urea breath analyser. Comparison to urease test and histopathological detection of *H. pylori*. *Gastroenterology* 2000; 118: A507.
66. Shirin H, Kawabata Y, Pinto JT, Soh JW, Murty V, Delohery T, Rivlin RS, **Moss SF**, Holt PR, Weinstein IB. Antiproliferative mechanisms of S-allylmercaptocysteine: potential chemopreventive effects on colon cancer. *Gastroenterology* 2000; 118: A525.
67. Holt PR, Arber N, O'Connor J, Halmos B, McGlynn C, **Moss SF**, Pou R, Yang K, Fan K, Newmark H, Lipkin ML. Serum 25 Hydroxy vitamin D<sub>3</sub> inhibits proliferation of colonic epithelial cells in subjects at high risk for colon neoplasia. *Gastroenterology* 2000; 118: A276.
68. Shirin H, Pinto J, Liu L, Merzianu M, Sordillo EM, **Moss SF**. *Helicobacter pylori* decreases gastric mucosal glutathione. *Gut* 2000; 47 (suppl 1): A33.

69. Peek RM, Wirth HP, Tham KT, Richmond HT, Ando T, Kim S-K, Blaser MJ, **Moss SF**. Infection of Mongolian gerbils with *H. pylori* strains associated with differential cancer risks reflects the pathological response of the human host. *Gastroenterology* 2000; 118: A763.
70. Bhagat G, Hanzely Z, **Moss S**, Shendrik I, Rotterdam H. Mott cells: an integral component of *H. pylori* gastritis. International Association of Pathologists, Nagoya, Japan, October 2000.
71. Shirin H, **Moss SF**, Kancherla S, Kancherla K, Holt PR, Weinstein IB, Sordillo EM. Ability of NSAIDs to suppress *Helicobacter pylori* growth *in vitro*. *Gastroenterology* 2001; 120: A-589.
72. Shirin H, Hibshoosh H, Kawabata Y, Weinstein IB, **Moss SF**. p16<sup>Ink4a</sup> is overexpressed in *H. pylori*-associated gastritis and correlates with increased epithelial apoptosis. *Gastroenterology* 2001; 120: A743.
73. Israel DA, Salama N, Arnold CN, **Moss SF**, Ando T, Wirth H-P, Tham KT, Camorlinga M, Falkow S, Peek RM. *Helicobacter pylori* whole genome microarray identifies differences in genetic composition related to pathogenesis among strains that induce distinct clinical outcomes. *Gastroenterology* 2001; 120: A100.
74. Shirin H, Sadan O, Shevah O, **Moss SF**, Bruck R, Glezerman M, Avni Y. *H. pylori* is associated with gastrointestinal symptoms in the first trimester but not later in pregnancy. *Gut* 2001;49 (suppl 11):A31.
75. Shirin H, Hibshoosh H, Kawabata Y, Weinstein IB, **Moss SF**. Increased expression of the cyclin-dependent kinase inhibitor p16<sup>Ink4a</sup> in *H. pylori*-associated chronic gastritis. *Gut* 2001; 49 (suppl 11): A39.
76. Shirin H, **Moss SF**, Stark, Holt PR, Weinstein IB, Sordillo EM. Inhibition of *H. pylori* by the non-steroidal anti-inflammatory drug sulindac. *Gut* 2001; 49 (suppl 11): A61.
77. Eguchi H, Herschenhous N, **Moss SF**. Regulation of gastric epithelial cell p27<sup>kip1</sup> expression by *Helicobacter pylori*. *Proc Am Assoc Cancer Res* 2002; 43: 623.
78. Eguchi H, Herschenhous N, **Moss SF**. *Helicobacter pylori* increases proteasomal activity to degrade p27<sup>kip1</sup> in gastric epithelial cells. *Gastroenterology* 2002; 122: A1.
79. Shirin H, Shevah O, Frenkel D, Levine A, Bruck R, **Moss SF**, Niv Y, Avni Y. Effect of proton pump inhibitors on the continuous real time 13C-urea breath test. *Gastroenterology* 2002; 122: A46.
80. Eguchi H, **Moss SF**. *Helicobacter pylori* increases the degradation of p27<sup>kip1</sup> in gastric epithelial cells. *Proc Am Assoc Cancer Res* 2003; 44: 487.
81. Davis GC, Kethu SR, Ramzan UC, Moss SF. Are we performing unnecessary endoscopies for suspected upper gastrointestinal bleeding in hospitalized patients? *Gastroenterology* 2003; 124: A-508.
82. Kuzushita N, Aswad B, Park M-J, **Moss SF**. Deficiency of p27 leads to increased gastric epithelial and inflammatory responses to *Helicobacter pylori*. *Gastroenterology* 2003; 124: A5-A6.
83. Eguchi H, **Moss SF**. Degradation of p27<sup>kip1</sup> by *Helicobacter pylori* in gastric epithelial cells is proteasome-dependent but independent of ubiquitination or mitogen-activated protein kinase (MAPK) phosphorylation. *Gastroenterology* 2003 124: A-43
84. Shirin H, Kravtsov V, Shahmurov M, Bruck R, **Moss SF**, Avni Y, Avinoach I. p27<sup>kip1</sup> expression is inversely related to the grade of gastric malt lymphoma, irrespective of disease stage. *Gastroenterology* 2003; 124: A-111.
85. Shirin H, Shevah O, Levine A, **Moss SF**, Niv Y, Bruck R, Avni Y. Effect of high dose citric acid on proton pump inhibitor (PPI) induced false negative 13C-urea breath tests: comparison between omeprazole, pantoprazole and lansoprazole. *Gastroenterology* 2003; 124: A-58.
86. **Moss SF**, Kim SS, Carpentier S, Eguchi H. Low levels of p27<sup>kip1</sup> in gastric cells impairs the apoptotic response to *Helicobacter pylori* without influencing spontaneous apoptosis. *Proc Am Assoc Cancer Res* 2004; 45: abstract 3216.
87. Kim SS, Meitner P, Konkin TA, Cho YS, Resnick MB, **Moss SF**. Expression of skp2, p27's F-box protein, is increased by *H. pylori* in chronic gastritis and is inversely related to gastric epithelial p27. *Gastroenterology* 2004; 126: A-59.

88. Eguchi H, Kim SS, Carpentier S, **Moss SF**. p27<sup>kip1</sup> regulates the apoptotic response of gastric epithelial cells to *Helicobacter pylori*. *Gastroenterology* 2004; 126: A-409.
89. Park MJ, Shakhmurov M, Kuzushita N, Wands JR, **Moss SF**, Shirin H. p27<sup>kip1</sup> deficiency does not increase susceptibility to T cell-mediated Con A-induced liver damage. *Gastroenterology* 2005; 128: A727.
90. Gavilanez M, Konkin T, Newton E, Bhattacharya B, Wilson B, **Moss SF**, Resnick MB. Expression of claudin 1 and claudin 4 in gastric adenocarcinomas. *Gastroenterology* 2005; 128: A399.
91. Kuzushita N, Rogers AB, Monti NA, Park MJ, Aswad BI, Shirin H, Koff A, Eguchi E, **Moss SF**. p27<sup>kip1</sup> Deficiency confers susceptibility to gastric carcinogenesis in *Helicobacter pylori* infected mice. *Gastroenterology* 2005; 128: A108.
92. Cristofaro P, Nasir A, Konkin T, Hovanesian V, Monfils, PR, Resnick MB, Ramratnam B, **Moss SF**. siRNA therapy of inflammatory bowel disease. *Gastroenterology* 2006; 130 (suppl 2): A-343.
93. Resnick MB, Sabo E, Kim SS, Cho YS, Meitner P, Kim HK, Tavares R, **Moss SF**. Global analysis of the human gastric epithelial transcriptome altered by *H. pylori* eradication in vivo. *Gastroenterology* 2006; 130 (suppl 2): A-60.
94. Wolff JH, Potter J, Lattimore W, Resnick MB, Murphy B, **Moss SF**. The spiraling use of CT for abdominal pain: is colonoscopy necessary if colonic thickening is reported? *Gastroenterology* 2006; 130 (suppl 2): A-460.